Background: Only few ES-SCLC patients experience long-term survival benefit by maintenance IT. Adipokines-induced metabolic meta-inflammation has been related to enhanced responsiveness to IT in obese patients; however, their prognostic role in SCLC is currently controversial. Methods: Pre-treatment CT scan was used for determining distribution of abdominal adiposity, and blood samples were collected at fasting for measuring glycemia, insulin, ghrelin, leptin and adipokines (TNF-α, IFN-γ, IL-6 and MCP-1). Patients with known history of DM type II or metabolic syndrome with HOMA index > 2.5 were considered insulin resistant (IR). Results: In ES-SCLC pts receiving maintenance IT, increased leptin concentration and higher leptin/visceral adipose tissue (VAT) ratio were significantly associated with prolonged PFS. By applying a hierarchical clustering algorithm, we identified a cluster of patients characterized by higher leptin values and lower pro-inflammatory cytokines (TNF-α, IFN-γ and IL-6) who experienced longer PFS (13.2 vs 8.05 months; HR: 0.42 [0.18-0.93] p = 0.02) and OS (18.04 vs 12.09 mo; HR: 0.53 [0.25-1.29] p = 0.07). Conclusions: Adipokines can play a crucial role to determining effectiveness of anti-cancer immunotherapy. The role of metabolic immune dysfunctions needs further pre-clinical validation and is currently investigated in the larger prospective cohort.

Vita, E., Stefani, A., Piro, G., Mastrantoni, L., Cintoni, M., Cicchetti, G., Sparagna, I., Monaca, F., Horn, G., Russo, J., Barone, D., Di Salvatore, M., Trisolini, R., Lococo, F., Mazzarella, C., Cancellieri, A., Carbone, C., Larici, A. R., Mele, M. C., Pilotto, S., Milella, M., Tortora, G., Bria, E., Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC), <<CANCER IMMUNOLOGY, IMMUNOTHERAPY>>, 2023; 72 (11): 3803-3812. [doi:10.1007/s00262-023-03533-0] [https://hdl.handle.net/10807/261238]

Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)

Vita, Emanuele;Stefani, Alessio;Mastrantoni, Luca;Cintoni, Marco;Cicchetti, Giuseppe;Sparagna, Ileana;Monaca, Federico;Horn, Guido;Russo, Jacopo;Barone, Diletta;Di Salvatore, Mariantonietta;Trisolini, Rocco;Lococo, Filippo;Cancellieri, Alessandra;Carbone, Carmine;Larici, Anna Rita;Mele, Maria Cristina;Tortora, Giampaolo;Bria, Emilio
2023

Abstract

Background: Only few ES-SCLC patients experience long-term survival benefit by maintenance IT. Adipokines-induced metabolic meta-inflammation has been related to enhanced responsiveness to IT in obese patients; however, their prognostic role in SCLC is currently controversial. Methods: Pre-treatment CT scan was used for determining distribution of abdominal adiposity, and blood samples were collected at fasting for measuring glycemia, insulin, ghrelin, leptin and adipokines (TNF-α, IFN-γ, IL-6 and MCP-1). Patients with known history of DM type II or metabolic syndrome with HOMA index > 2.5 were considered insulin resistant (IR). Results: In ES-SCLC pts receiving maintenance IT, increased leptin concentration and higher leptin/visceral adipose tissue (VAT) ratio were significantly associated with prolonged PFS. By applying a hierarchical clustering algorithm, we identified a cluster of patients characterized by higher leptin values and lower pro-inflammatory cytokines (TNF-α, IFN-γ and IL-6) who experienced longer PFS (13.2 vs 8.05 months; HR: 0.42 [0.18-0.93] p = 0.02) and OS (18.04 vs 12.09 mo; HR: 0.53 [0.25-1.29] p = 0.07). Conclusions: Adipokines can play a crucial role to determining effectiveness of anti-cancer immunotherapy. The role of metabolic immune dysfunctions needs further pre-clinical validation and is currently investigated in the larger prospective cohort.
2023
Inglese
Vita, E., Stefani, A., Piro, G., Mastrantoni, L., Cintoni, M., Cicchetti, G., Sparagna, I., Monaca, F., Horn, G., Russo, J., Barone, D., Di Salvatore, M., Trisolini, R., Lococo, F., Mazzarella, C., Cancellieri, A., Carbone, C., Larici, A. R., Mele, M. C., Pilotto, S., Milella, M., Tortora, G., Bria, E., Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC), <<CANCER IMMUNOLOGY, IMMUNOTHERAPY>>, 2023; 72 (11): 3803-3812. [doi:10.1007/s00262-023-03533-0] [https://hdl.handle.net/10807/261238]
File in questo prodotto:
File Dimensione Formato  
leptin.pdf

accesso aperto

Licenza: Creative commons
Dimensione 1.59 MB
Formato Adobe PDF
1.59 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/261238
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact